Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative, pivotal, phase III trial of spray-on transdermally delivered testosterone [Testagen TDS] versus gel testosterone for male hormone replacement

Next Previous
X
Search
Trial Profile

Comparative, pivotal, phase III trial of spray-on transdermally delivered testosterone [Testagen TDS] versus gel testosterone for male hormone replacement

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone (Primary) ; Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 19 Apr 2016 According to a TransDermal Delivery Solutions media release, the Company has received regulatory approval for pivotal clinical trials of Testagen HypoSpray from the British National Health Services and the Medicine and Health Products Review Authority. The company expects to initiate this trial in next few weeks.
    • 26 Aug 2013 New trial record
    • 22 Aug 2013 Planned initiation date changed from 1 Mar 2009 to 1 Dec 2013, based on information in a Transdermal Delivery Solutions Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top